| Drug NDC: | 63083-6045 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Pop Detox 6045 |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Proprietary Name Base: | Pop Detox |
| The base of the Brand/Proprietary name excluding its suffix. | |
| Proprietary Name Suffix: | 6045 |
| A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Pop Detox |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Professional Complementary Health Formulas |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN - 60 [hp_X]/59mL ALUMINUM - 12 [hp_X]/59mL ARCTIUM LAPPA ROOT OIL - 3 [hp_X]/59mL ARSENIC TRIOXIDE - 12 [hp_X]/59mL BEEF KIDNEY - 6 [hp_X]/59mL BEEF LIVER - 6 [hp_X]/59mL BERBERIS VULGARIS ROOT BARK - 6 [hp_X]/59mL BOS TAURUS BRAIN - 6 [hp_X]/59mL BOS TAURUS GALLBLADDER - 6 [hp_X]/59mL BOS TAURUS LYMPH VESSEL - 6 [hp_X]/59mL Load more... CALENDULA OFFICINALIS FLOWERING TOP - 4 [hp_X]/59mL CAMPHECHLOR - 30 [hp_X]/59mL CHELIDONIUM MAJUS WHOLE - 6 [hp_X]/59mL CHOLESTEROL - 12 [hp_X]/59mL EQUISETUM ARVENSE TOP - 4 [hp_X]/59mL FENSON - 30 [hp_X]/59mL GELSEMIUM SEMPERVIRENS ROOT - 6 [hp_X]/59mL GOLD - 12 [hp_X]/59mL HEPTACHLOR - 30 [hp_X]/59mL HEXACHLOROBENZENE - 30 [hp_X]/59mL JUNIPERUS COMMUNIS VAR. SAXATILIS WHOLE - 4 [hp_X]/59mL LYCOPODIUM CLAVATUM SPORE - 4 [hp_X]/59mL MALATHION - 30 [hp_X]/59mL METHOXYCHLOR - 30 [hp_X]/59mL MILK THISTLE - 3 [hp_X]/59mL PODOPHYLLUM - 6 [hp_X]/59mL RICINUS COMMUNIS SEED - 4 [hp_X]/59mL SILVER - 12 [hp_X]/59mL TRIFOLIUM PRATENSE FLOWER - 3 [hp_X]/59mL TURPENTINE OIL - 5 [hp_X]/59mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 15 Aug, 1984 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 21 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Professional Complementary Health Formulas |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000185371 N0000175629 N0000184306 M0000728 M0006342 N0000185017 N0000185508 N0000175723 N0000000177 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | DO80M48B6O CPD4NFA903 55DGS3F5YG S7V92P67HO 5HOC10FSIC W8N8R55022 1TH8Q20J0U A1YEE2DB8Z 9901V1E867 85I1Z426OV Load more... 18E7415PXQ 9924JQ4D5J 7E889U5RNN 97C5T2UQ7J 1DP6Y6B65Z DFC2HB4I0K 639KR60Q1Q 79Y1949PYO 7GLS9ACN3L 4Z87H0LKUY 360QM23QBR C88X29Y479 U5N7SU872W RIA79UD69L U946SH95EE 2S713A4VP3 7EK4SFN1TX 3M4G523W1G 4JS0838828 C5H0QJ6V7F |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | Cholinesterase Inhibitors [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | Non-Standardized Food Allergenic Extract [EPC] Standardized Chemical Allergen [EPC] Cholinesterase Inhibitor [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Allergens [CS] Dietary Proteins [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Cell-mediated Immunity [PE] Cholinesterase Inhibitor [EPC] Cholinesterase Inhibitors [MoA] Dietary Proteins [CS] Increased Histamine Release [PE] Meat Proteins [EXT] Non-Standardized Food Allergenic Extract [EPC] Standardized Chemical Allergen [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 63083-6045-2 | 59 mL in 1 BOTTLE, DROPPER (63083-6045-2) | 15 Aug, 1985 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.